ReviewCurrent opinion in nephrology and hypertension2012
Membranous nephropathy: the start of a paradigm shift.
Review in Current opinion in nephrology and hypertension, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Article
- Insulin restores renal neprilysin (NEP) and attenuates the shedding of urinary NEP and KIM-1 in diabetic Akita mice.Frontiers in pharmacology · 2025Article
- A Simplified Iohexol-Based Method to Measure Renal Function in Sheep Models of Renal Disease.Biology · 2020Article
- The investigative burden of membranous nephropathy in the UK.Clinical kidney journal · 2020Article
- Comprehensive expression profiles and bioinformatics analysis reveal special circular RNA expression and potential predictability in the peripheral blood of humans with idiopathic membranous nephropathy.Molecular medicine reports · 2019Article
- Role of Podocyte Injury in Glomerulosclerosis.Advances in experimental medicine and biology · 2019Review
- Kidney disease models: tools to identify mechanisms and potential therapeutic targets.Zoological research · 2018Review
- A Simple Method to Measure Renal Function in Swine by the Plasma Clearance of Iohexol.International journal of molecular sciences · 2018Article
- Review
- Two cases of idiopathic membranous nephropathy treated with rituximab.Kidney research and clinical practice · 2013Article
- American Society of Nephrology Quiz and Questionnaire 2012: glomerulonephritis.Clinical journal of the American Society of Nephrology : CJASN · 2013Article
- Biomarkers in nephrology: Core Curriculum 2013.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2013Review
- Coexistence of different circulating anti-podocyte antibodies in membranous nephropathy.Clinical journal of the American Society of Nephrology : CJASN · 2012Article
- Membranous nephropathy: Treatment outline and risk stratification.Avicenna journal of medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
purpose of reviewPrimary membranous nephropathy is a common glomerular disease characterized by sub-epithelial immune deposits that has become the prototype of an autoimmune glomerular disease. The purpose of this review is to highlight recent advances regarding the pathogenesis of membranous nephropathy as well as potential new therapies. RECENT
findingsThe discovery of two major podocyte antigens, neutral endopeptidase (NEP), involved in rare cases of neonatal membranous nephropathy, and the M-type phospholipase A2 receptor 1 (PLA2R1), the first antigen discovered in adults, have been major 'breakthroughs' in our understanding of the pathogenesis of human membranous nephropathy. Anti-PLA2R antibodies appear to predict activity of the disease as well as response to therapy. Pediatric and adult cases of membranous nephropathy occurring in the presence of circulating cationic bovine serum album (BSA) and anti-BSA antibodies have also been described, raising the possibility that food antigens may be involved in the development of membranous nephropathy. Moreover, the results of genetic susceptibility have become available. Exciting progress has also been made in the treatment of this disease including therapy with adrenocorticotropic hormone and rituximab. SUMMARY: Understanding disease pathogenesis is crucial in guiding patient evaluation and designing appropriate therapy. Recent discoveries have helped to elucidate the pathophysiology of membranous nephropathy and may facilitate a more patient-specific treatment approach in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.